Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Mucin-based Targeted Pancreatic Cancer Therapy

Author(s): Maria P. Torres, Subhankar Chakraborty, Joshua Souchek and Surinder K. Batra

Volume 18, Issue 17, 2012

Page: [2472 - 2481] Pages: 10

DOI: 10.2174/13816128112092472

Price: $65

Abstract

The prognosis of pancreatic cancer (PC) patients is very poor with a five-year survival of less than 5%. One of the major challenges in developing new therapies for PC is the lack of expression of specific markers by pancreatic tumor cells. Mucins are heavily Oglycosylated proteins characterized by the presence of short stretches of amino acid sequences repeated several times in tandem. The expression of several mucins including MUC1, MUC4, MUC5AC, and MUC16 is strongly upregulated in PC. Recent studies have also demonstrated a link between the aberrant expression and differential overexpression of mucin glycoproteins to the initiation, progression, and poor prognosis of the disease. These studies have led to increasing recognition of mucins as potential diagnostic markers and therapeutic targets in PC. In this focused review we present an overview of the therapies targeting mucins in PC, including immunotherapy (i.e. vaccines, antibodies, and radioimmunoconjugates), gene therapy, and other novel therapeutic strategies.

Keywords: Pancreatic cancer, mucins, targeted therapy


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy